The Food and Drug Administration approved daraxonrasib for advanced pancreatic cancer last month, with a clinical trial showing the new pill doubled median patient survival time to 13.2 months compared to 6.7 months with standard chemotherapy. The breakthrough targets a mutated KRAS enzyme long considered undruggable.
Advanced pancreatic cancer has long ranked among the deadliest malignancies, offering severely limited options to patients and typically yielding rapid disease progression. According to the National Cancer Institute, more than 67,000 people will receive a pancreatic cancer diagnosis in the United States in 2026, while nearly 57,000 are projected to die from the disease, leaving a five-year survival rate of 13.7 percent.
Targeting the Undruggable KRAS Enzyme
The newly approved medication, daraxonrasib, works by binding to and inhibiting a mutated enzyme called KRAS, which drives the growth of pancreatic cancer cells. For years, scientists considered KRAS and other RAS proteins impossible to drug because of their smooth molecular surfaces. Researchers broke through that barrier thanks in part to foundational laboratory discoveries from Harvard chemist Gregory Verdine, paving the way for California-based Revolution Medicines to create the drug.
Brian Wolpin, a professor of medicine at Harvard Medical School and holder of the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute, led the global phase 3 clinical trial for the medication, known as the RASolute 302 study. Wolpin presented the trial results in May at the annual meeting of the American Society of Clinical Oncology.
Clinical Trial Results and Patient Experience
In the phase 3 study of patients with previously treated metastatic pancreatic cancer, daraxonrasib doubled the median survival time to 13.2 months. Patients receiving the standard chemotherapy comparator reached a median survival of only 6.7 months.
Beyond extending life, the therapy altered the daily treatment experience. Wolpin noted that daraxonrasib is administered as a once-daily pill, sparing patients from spending five hours in infusion rooms, using chemotherapy pumps, or requiring central access via a port-a-cath. Side effects also generally run milder than traditional chemotherapy.
The preclinical data were very impressive, with evidence of substantial anti-tumor activity of the drug in the laboratory. However, efficacy in the laboratory does not guarantee success when a medication is given to patients.
Brian Wolpin, HMS professor of medicine and Dana-Farber Cancer Institute chair
The clinical signal first emerged during the phase 1 safety trial. Investigators observed that patients taking relatively low doses experienced a resolution of abdominal pain within weeks. Follow-up CT scans subsequently confirmed reductions in tumor burden.
Validation and the Shift in Clinical Outlook
The recent regulatory decision brought a sense of relief to researchers who have witnessed unsuccessful clinical trials in the field. Wolpin described the approval as a validation that rigorous and diligent science can deliver breakthroughs even in the toughest cancer types, while expressing hope that the development will alter deep-seated pessimism surrounding pancreatic cancer treatment.
While historical oncology training over twenty years ago introduced clinicians to patients succumbing to metastatic disease within three months, the new survival data point toward changing conditions. Wolpin discussed with the Harvard Gazette that the therapeutic advance holds potential to transform patient care within a decade, turning a corner on a diagnosis that previously proved extremely difficult to treat.
